Expert Perspectives on the Utility of Real-World Data in the Management of Plaque Psoriasis : Episode 7
IL-23 inhibitors for Plaque Psoriasis Treatment
Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.
EP: 1.Plaque Psoriasis: Current Expansion of the Therapeutic Landscape
EP: 2.Shifting Treatment Approaches to Plaque Psoriasis
EP: 3.Current Role of Topical Therapy for Plaque Psoriasis Treatment
EP: 4.Spectrum of Disease and Current Treatment Options for Plaque Psoriasis
EP: 5.Plaque Psoriasis: Escalating Treatment
EP: 6.Communication With Patients About Plaque Psoriasis Treatment
Now Viewing
EP: 7.IL-23 inhibitors for Plaque Psoriasis Treatment
EP: 8.Impact of Treatment Mode of Delivery on Patient Adherence and Plaque Psoriasis Treatment Selection
EP: 9.Long-Term Persistence of Biologic Treatment Options for Plaque Psoriasis
EP: 10.IL-23 Inhibitors and the Current Treatment Landscape for Plaque Psoriasis
EP: 11.Long Term Efficacy And Safety Data: IL-23 Inhibitors in Patients with Moderate to Severe Plaque Psoriasis
EP: 12.BMI and Background Comorbidities that Impact Plaque Psoriasis Treatment
EP: 13.Plaque Psoriasis: Older Populations and Skin of Color
EP: 14.Looking Ahead at Clinical Trial Metrics for Plaque Psoriasis
EP: 15.Plaque Psoriasis: Future Therapeutic Pipeline
Recent Videos
Related Content
